Tricyclic Compounds as Inhibitors of Immunosuppression Mediated By Tryptophan Metabolization
申请人:NEWLINK GENETICS CORPORATION
公开号:US20160060266A1
公开(公告)日:2016-03-03
Presently provided are inhibitors of IDO and TDO and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase and tryptophan 2,3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosuppression associated with an infectious disease.
目前提供的是IDO和TDO的抑制剂及其制药组合物,用于调节吲哚酮2,3-二氧化酶和色氨酸2,3-二氧化酶的活性;治疗免疫抑制;治疗从色氨酸降解抑制中受益的医疗状况;增强包括给予抗癌药剂在内的抗癌治疗的效果;治疗与癌症相关的肿瘤特异性免疫抑制;以及治疗与传染病相关的免疫抑制。